Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis

Figures & data

Figure 1. Study selection flow diagram.

Table 1. Study and patient characteristics.

		Study Characteristics			Patient Characteristics
Author, Publication Year	Study Name	Study Design	Country	Median Follow up Period (years)	N	Median Age (yrs.)	Size of Tumor: % 2 cm or less	Nodal Status: % Positive Nodes	HR Status: % HR(+)	% Mastectomy
Cameron et al, 2017 [26]	HERA	RCT	39 countries from Europe, Canada, South Africa, Australia, New Zealand, Asia Pacific, Japan, Eastern Europe, Central and South America	11	3399	49	38.96 1cm: 0 %	57.30	50	57.83
Perez et al, 2014 [27]	N9831 +B31	RCT	USA	8.4	4046	-	39.53	93.03	54.75	38.98
Advani et al 2016 [29]	N9831	RCT	USA	9.2	1944	49	-	-	-	-
Romond et al 2012 [28]	B31	RCT	USA	7	2119	49	-	-	-	-
Joensuu et al, 2014 [33]	FinXX	RCT	41 countries from Europe, South Africa, Australia, South America, Asia Pacific	5.4	284	Int grp: 52.2 Control grp: 50.5	37.67	83.45	57.04	68.66
Slamon et al, 2011 [30]	BCIRG006	RCT	Finland	6.7	2147	49	39.80 1cm: 4.61%	71.38	54	60.7
Joensuu et al, 2009 [31]	FinHER	RCT	Finland	5.2	231	50.9	34.91 1cm: 6.90%	89	72.2	-
Spielmann et al, 2009 [32]	PACS-04	RCT	France and Belgium	3.9	528	48	43.55	100	40.34	36.36

N = sample size; HR = Hormone-Receptor; HR(+) = Hormone-Receptor Positive; RCT = Randomized controlled trial;

Figure 2. Forest plot for overall HR of OS.

Figure 3. Forest plot for overall HR of DFS.

Figure 4. Forest plot for overall RR of CHF.

Figure 5. Forest plot for overall RR of LVEF Decline.

Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. [cited 2017 Jul 1]; Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

 Google Scholar

Towse A. Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment. Value Health. 2010 Jun;13(Suppl 1):S30–S32.

 PubMedGoogle Scholar

Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;23(31):7811–7819.

 Google Scholar

Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;369(9555):29–36.

 Google Scholar

Joensuu H, Bono P, Kataja V, et al. Fluorouacil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009;27(34):5685–5692.

 PubMed Web of Science ®Google Scholar

Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2012;30(31):3792–3799.

 PubMed Web of Science ®Google Scholar

Advani PP, Ballman KV, Dockter TJ, et al. Long term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016;23(31):7811–7819.

 Google Scholar

Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.

 PubMed Web of Science ®Google Scholar